Out of the 27 Nifty50 companies that have reported their quarterly numbers so far, 12 have reported results that beat Street expectations, seven fell short of meeting investor expectations. Two companies reported in-line results while the rest six came out with a mixed set of numbers.
Here’s what an ET NOW poll of analysts suggests on the earnings today:
The NBFC is expected to report a 33 per cent YoY rise in net profit at Rs 4,003 crore compared with Rs 3,000 crore in the year-ago quarter. Net interest income (NII) is expected to go up by 15 per cent YoY to Rs 4,728 crore from Rs 4,125 crore. Pre-provision operating profit is seen up by 19 per cent YoY at Rs 5,494 crore from Rs 4,591 crore. NIM is seen at 3 per cent compared with 3.2 per cent in the March quarter and 3.1 per cent in the year-ago quarter. AUM growth is likely to be healthy at 15-17 per cent YoY.
Outlook on margin, demand in individual and non-individual segments and asset quality trend in the non-individual segment will be keenly watched, analysts told ET NOW.
The drug maker is expected to report a consolidated net profit of Rs 1,850 crore compared with Rs 1,444 crore in the same quarter last year. Sales are seen at Rs 10,425 crore against Rs 9,719 crore YoY. Ebitda, as per the poll, is seen at Rs 2,575 crore compared with Rs 2,821 crore YoY. Ebitda margin is seen falling to 25 per cent from 29 per cent YoY. That said, the margin may expand sequentially. Specialty sales may drive Ebitda margin expansion. India sales should decline 3 per cent YoY, given the 10 per cent of base sales for Covid, the analyst poll suggested.
The drug maker is expected to report a net profit of Rs 601 crore compared with Rs 715 crore in the same quarter last year. Sales are seen falling to Rs 5,275 crore against Rs 5,504 crore YoY. Ebitda, as per the poll, is seen at Rs 1,050 crore compared with Rs 1,346 crore YoY. Ebitda margin is seen falling to 19.9 per cent from 24 per cent YoY. India sales are expected to fall 17 per cent YoY, largely due to the high base of Covid drug sales. US sales are expected to be flattish sequentially, despite a higher share in Lanreotide.
(Disclaimer: Recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of Economic Times)